Oncobiologics (NASDAQ:OTLK) Director Faisal Ghiath Sukhtian Acquires 95,398 Shares of Stock

Oncobiologics, Inc. (NASDAQ:OTLK) Director Faisal Ghiath Sukhtian acquired 95,398 shares of the stock in a transaction dated Wednesday, July 29th. The shares were bought at an average price of $1.05 per share, for a total transaction of $100,167.90. Following the transaction, the director owned 220,972 shares in the company, valued at approximately $232,020.60. This represents a 75.97% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Oncobiologics Stock Performance

Shares of NASDAQ:OTLK opened at $1.00 on Thursday. Oncobiologics, Inc. has a 52-week low of $0.16 and a 52-week high of $3.39. The firm has a fifty day moving average of $1.22 and a 200 day moving average of $0.66. The firm has a market capitalization of $148.59 million, a PE ratio of -0.85 and a beta of 0.77.

Oncobiologics (NASDAQ:OTLK) last released its quarterly earnings results on Friday, May 15th. The company reported ($0.16) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.04). The business had revenue of $0.13 million during the quarter, compared to analyst estimates of $4.39 million. On average, sell-side analysts forecast that Oncobiologics, Inc. will post -0.49 EPS for the current fiscal year.

Hedge Funds Weigh In On Oncobiologics

Hedge funds have recently modified their holdings of the company. Goldman Sachs Group Inc. raised its stake in shares of Oncobiologics by 74.1% during the first quarter. Goldman Sachs Group Inc. now owns 103,524 shares of the company’s stock valued at $126,000 after acquiring an additional 44,063 shares during the last quarter. AQR Capital Management LLC grew its stake in shares of Oncobiologics by 42.7% in the first quarter. AQR Capital Management LLC now owns 84,671 shares of the company’s stock worth $103,000 after purchasing an additional 25,351 shares during the last quarter. Finally, Russell Investments Group Ltd. grew its stake in shares of Oncobiologics by 865.2% in the second quarter. Russell Investments Group Ltd. now owns 24,477 shares of the company’s stock worth $39,000 after purchasing an additional 21,941 shares during the last quarter. Hedge funds and other institutional investors own 11.20% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on OTLK shares. Wall Street Zen downgraded Oncobiologics from a “hold” rating to a “sell” rating in a research report on Saturday, July 18th. Weiss Ratings cut shares of Oncobiologics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday. HC Wainwright lifted their price target on shares of Oncobiologics from $0.50 to $1.60 and gave the stock a “neutral” rating in a research note on Monday. BTIG Research upgraded shares of Oncobiologics from a “neutral” rating to a “buy” rating and set a $4.00 price objective for the company in a report on Monday. Finally, Ascendiant Capital Markets upped their price objective on shares of Oncobiologics from $6.00 to $10.00 and gave the company a “buy” rating in a research note on Thursday, June 11th. Two analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $4.65.

Key Headlines Impacting Oncobiologics

Here are the key news stories impacting Oncobiologics this week:

• Positive Sentiment: Director Faisal Ghiath Sukhtian bought 95,398 shares at an average price of $1.05, investing approximately $100,168. The purchase increased his direct ownership by nearly 76% to 220,972 shares, a potential signal of insider confidence. SEC insider transaction filing
• Positive Sentiment: BTIG Research upgraded OTLK to “Buy,” providing a stronger bullish view than the existing neutral coverage. BTIG Research upgrades Oncobiologics
• Positive Sentiment: HC Wainwright substantially improved its forecasts for 2027, raising full-year EPS expectations to a loss of $0.03 from a loss of $0.21. It also projects a return to profitability in 2028, with EPS of $0.09, followed by $0.15 in 2029 and $0.32 in 2030. The firm maintains a $1.60 price target.
• Neutral Sentiment: HC Wainwright raised estimates for several 2026–2027 quarters, but still rates OTLK “Neutral.” Its FY2026 EPS forecast was reduced to a loss of $0.47 from $0.42, indicating that near-term profitability remains uncertain.
• Negative Sentiment: A separate report on LYTENAVA—identified in the article as an Outlook Therapeutics program—cited significant cash constraints and the need for funding or a partnership before a U.S. launch. Although the therapy has FDA and European approval, competition in the anti-VEGF market could make commercialization difficult. Caution on LYTENAVA approval and cash needs

About Oncobiologics

Oncobiologics, Inc is a clinical-stage biopharmaceutical company specializing in the development of biosimilar therapeutics for cancer and autoimmune diseases. Leveraging recombinant DNA technology and advanced formulation platforms, the company aims to create high-quality, cost-effective alternatives to originator biologic drugs. Oncobiologics’ research focus includes monoclonal antibodies and growth factors that support oncology treatment and immunomodulation.

Founded in 2005 and headquartered in Marlborough, Massachusetts, Oncobiologics maintains research facilities in the Greater Boston area and an integrated manufacturing site in Hyderabad, India, through its wholly owned subsidiary.